MCID: OPN001
MIFTS: 53

Open-Angle Glaucoma

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Open-Angle Glaucoma

MalaCards integrated aliases for Open-Angle Glaucoma:

Name: Open-Angle Glaucoma 12 15 17
Glaucoma, Open-Angle 45 74
Open Angle Glaucoma 12
Pigmentary Glaucoma 12
Wide-Angle Glaucoma 12
Glaucoma Open-Angle 56
Glaucoma Simplex 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1067
MeSH 45 D005902
NCIt 51 C34641
SNOMED-CT 69 46168003 84494001
UMLS 74 C0017612

Summaries for Open-Angle Glaucoma

Disease Ontology : 12 A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage.

MalaCards based summary : Open-Angle Glaucoma, also known as glaucoma, open-angle, is related to glaucoma 1, open angle, a and glaucoma, primary open angle. An important gene associated with Open-Angle Glaucoma is MYOC (Myocilin), and among its related pathways/superpathways are Degradation of the extracellular matrix and Elastic fibre formation. The drugs Latanoprost and Travoprost have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial, and related phenotypes are homeostasis/metabolism and vision/eye

Related Diseases for Open-Angle Glaucoma

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Open Angle, I

Diseases related to Open-Angle Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 glaucoma 1, open angle, a 34.4 CYP1B1 MYOC OPTN
2 glaucoma, primary open angle 32.7 ASB10 CAV2 CYP1B1 ELN GSTM1 LOXL1
3 ocular hypertension 32.4 MYOC OPTN TMCO1
4 exfoliation syndrome 32.4 ELN LOXL1 MMP1
5 primary angle-closure glaucoma 31.7 CYP1B1 MYOC OPTN
6 low tension glaucoma 31.7 MYOC OPTN TBK1 WDR36
7 optic nerve disease 31.3 MYOC OPA1 OPTN
8 glaucoma 3, primary infantile, b 31.2 CYP1B1 LTBP2
9 glaucoma, normal tension 31.0 LOXL1 OPA1 OPTN
10 glaucoma 3, primary congenital, a 31.0 CYP1B1 LTBP2 MYOC OPTN
11 primary congenital glaucoma 30.9 CYP1B1 LTBP2 MYOC OPTN WDR36
12 chronic closed-angle glaucoma 30.6 OPTN TGFB2
13 glaucoma-related pigment dispersion syndrome 30.5 CYP1B1 LOXL1
14 megalocornea 30.4 LTBP2 OPTN
15 neovascular glaucoma 30.3 OPTN TGFB2
16 juvenile glaucoma 29.3 CYP1B1 ELN MYOC NTF4 OPTN TGFB2
17 residual stage of open angle glaucoma 12.6
18 glaucoma 1, open angle, f 12.3
19 glaucoma 1, open angle, p 12.2
20 glaucoma 1, open angle, g 12.0
21 glaucoma 1, open angle, o 12.0
22 intraocular pressure quantitative trait locus 11.9
23 glaucoma 1, primary open angle, c 11.5
24 glaucoma 1, open angle, d 11.5
25 cataract 10.9
26 myopia 10.7
27 neuropathy 10.6
28 diabetes mellitus 10.6
29 helicobacter pylori infection 10.5
30 ischemic optic neuropathy 10.5
31 hypothyroidism 10.5
32 macular degeneration, age-related, 1 10.4
33 alzheimer disease 10.4
34 acrofrontofacionasal dysostosis 10.4 CYP1B1 OPTN
35 nonarteritic anterior ischemic optic neuropathy 10.4
36 retinal vein occlusion 10.4
37 hydrophthalmos 10.4 CYP1B1 LTBP2 OPTN
38 dementia 10.3
39 axenfeld-rieger syndrome, type 2 10.3 ASB10 OPTN
40 axenfeld-rieger syndrome 10.3 ASB10 CYP1B1 OPTN
41 early-onset glaucoma 10.3 CYP1B1 MYOC
42 aging 10.3
43 yemenite deaf-blind hypopigmentation syndrome 10.3
44 macular retinal edema 10.3
45 excessive tearing 10.3 CYP1B1 LTBP2 MYOC OPTN
46 sleep apnea 10.2
47 central retinal vein occlusion 10.2
48 senile cataract 10.2
49 refractive error 10.2
50 migraine with or without aura 1 10.1

Comorbidity relations with Open-Angle Glaucoma via Phenotypic Disease Network (PDN):


Anatomical Narrow Angle Borderline Glaucoma Glaucoma, Primary Open Angle
Hypertension, Essential Ocular Hypotension

Graphical network of the top 20 diseases related to Open-Angle Glaucoma:



Diseases related to Open-Angle Glaucoma

Symptoms & Phenotypes for Open-Angle Glaucoma

MGI Mouse Phenotypes related to Open-Angle Glaucoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.73 CAV2 CYP1B1 LMX1B LOXL1 MMP1 NTF4
2 vision/eye MP:0005391 9.23 CYP1B1 LMX1B LTBP2 MYOC OPA1 OPTC

Drugs & Therapeutics for Open-Angle Glaucoma

Drugs for Open-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130209-82-4 5311221 5282380
2
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 157283-68-6 5282226
3
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 155206-00-1 5311027
4
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 120279-96-1 3154 5284549
5
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 26839-75-8 33624 5478
6
Ketorolac Approved Phase 4,Not Applicable 66635-83-4, 74103-06-3 3826
7
Brinzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138890-62-7 68844
8
Apraclonidine Approved Phase 4,Not Applicable 66711-21-5 2216
9
Sorbitol Approved Phase 4 50-70-4 5780
10
Pilocarpine Approved, Investigational Phase 4,Not Applicable 54-71-7, 92-13-7 5910
11
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
12
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
13
Bevacizumab Approved, Investigational Phase 4,Not Applicable 216974-75-3
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
15
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
16
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 444025 9865442
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
20
SB-649868 Experimental, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 110-16-7, 110-17-8 444972
21 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Ketorolac Tromethamine Phase 4,Not Applicable
31 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 70359-46-5
32 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
36 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
38 Anesthetics Phase 4,Phase 1,Phase 2,Not Applicable
39 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
42 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Lubricant Eye Drops Phase 4,Phase 3,Phase 2,Not Applicable
45 Anti-Infective Agents, Local Phase 4,Phase 2
46 Benzalkonium Compounds Phase 4,Phase 2
47 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
48 Luteolytic Agents Phase 4,Phase 3
49 Cloprostenol Phase 4,Phase 3
50 Contraceptive Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 748)
# Name Status NCT ID Phase Drugs
1 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
2 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
3 Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients Unknown status NCT02789293 Phase 4
4 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
5 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
6 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
7 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
8 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
9 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
10 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
11 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
12 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
13 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma Unknown status NCT01494974 Phase 4
14 Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma Completed NCT01956942 Phase 4
15 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Completed NCT01443988 Phase 4 Travoprost
16 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
17 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Completed NCT01252888 Phase 4
18 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects Completed NCT00326040 Phase 4
19 A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
20 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Completed NCT01252862 Phase 4
21 24-hour Intraocular Pressure (IOP) Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-angle Glaucoma Completed NCT00397241 Phase 4 Drug: dorzolamide/timolol;Drug: latanoprost/timolol;dorzolamide/timolol and latanoprost;placebo (artificial tears)
22 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
23 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
24 Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost Completed NCT03331770 Phase 4 Latanoprost Ophthalmic Product
25 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
26 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
27 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
28 Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) Completed NCT00913029 Phase 4 latanoprost/timolol
29 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
30 A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma Completed NCT00887029 Phase 4 DuoTrav (travoprost-timolol ophthalmic drops);Xalacom (latanoprost-timolol ophthalmic drops)
31 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
32 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
33 Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
34 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
35 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
36 Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma Completed NCT00444080 Phase 4
37 Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
38 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
39 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
40 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
41 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
42 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822055 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
43 Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) Completed NCT02167035 Phase 4 Combigan Two Times Daily (BID);Simbrinza Three Times Daily (TID)
44 Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study Completed NCT00698438 Phase 4
45 Efficacy And Safety of Pneumatic Trabeculoplasty Completed NCT01540331 Phase 4
46 Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) Completed NCT02863705 Phase 4 brimonidine tartrate/timolol malate Ophthalmic Solution;bimatoprost ophthalmic solution 0.01%
47 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
48 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
49 Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
50 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)

Search NIH Clinical Center for Open-Angle Glaucoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: glaucoma, open-angle

Genetic Tests for Open-Angle Glaucoma

Anatomical Context for Open-Angle Glaucoma

MalaCards organs/tissues related to Open-Angle Glaucoma:

42
Eye, Testes, Endothelial, Retina, Brain, Cortex, Bone

Publications for Open-Angle Glaucoma

Articles related to Open-Angle Glaucoma:

(show top 50) (show all 3393)
# Title Authors Year
1
Cataract Surgery and Rate of Visual Field Progression in Primary Open-Angle Glaucoma. ( 30703355 )
2019
2
Prospective, Randomized, Controlled Pivotal Trial of iStent inject Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results. ( 30880108 )
2019
3
Re: Samuelson et al.: A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: The HORIZON study (Ophthalmology. 2019;126:29-37). ( 30577921 )
2019
4
A Comparison Of Resource Use And Costs Of Caring For Patients With Exfoliation Syndrome Glaucoma Versus Primary Open-Angle Glaucoma. ( 30629910 )
2019
5
Thiol-disulphide homeostasis and serum ischemia modified albumin levels in patients with primary open-angle glaucoma. ( 30868923 )
2019
6
Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. ( 30614563 )
2019
7
Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension. ( 30617814 )
2019
8
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( 30839416 )
2019
9
Posterior scleral deformations around optic disc are associated with visual field damage in open-angle glaucoma patients with myopia. ( 30875403 )
2019
10
Different Disc Characteristics Associated With High Myopia and the Location of Glaucomatous Damage in Primary Open-Angle Glaucoma and Normal-Tension Glaucoma. ( 30789526 )
2019
11
360° ab-interno trabeculotomy in refractory primary open-angle glaucoma. ( 30666087 )
2019
12
Peripapillary Vessel Density in Glaucomatous Eyes: Comparison Between Pseudoexfoliation Glaucoma and Primary Open-angle Glaucoma. ( 30676407 )
2019
13
Peripapillary Vessel Density in Pseudoexfoliation Glaucoma and Primary Open-Angle Glaucoma. ( 30676410 )
2019
14
Potential Biomarkers for Primary Open-Angle Glaucoma Identified by Long Noncoding RNA Profiling in the Aqueous Humor. ( 30677397 )
2019
15
The Risk of Primary Open-Angle Glaucoma Following Vitreoretinal Surgery-A Population-based Study. ( 30683306 )
2019
16
XEN® Gel Stent for management of chronic open angle glaucoma: A review of the literature. ( 30683533 )
2019
17
The Risk of Primary Open-Angle Glaucoma Following Vitreoretinal Surgery-A Population-based Study. ( 30686476 )
2019
18
Peripapillary Vessel Density in Glaucomatous Eyes: Comparison Between Pseudoexfoliation Glaucoma and Primary Open-angle Glaucoma. ( 30688841 )
2019
19
Incidence of Open-angle Glaucoma in Newly Diagnosed Retinal Vein Occlusion: A Nationwide Population-based Study. ( 30689606 )
2019
20
Increased Aqueous Humor Symmetric Dimethylarginine Level in Patients with Primary Open Angle Glaucoma. ( 30707048 )
2019
21
Trabecular microbypass stent implantation in pseudophakic eyes with open-angle glaucoma: Long-term results. ( 30709629 )
2019
22
The EX-PRESS glaucoma shunt versus nonpenetrating deep sclerectomy with Esnoper implant in combined surgery for open-angle glaucoma: a prospective randomized study. ( 30714336 )
2019
23
Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Alzheimer's Disease: A Comparison of Eyes of Patients with Alzheimer's Disease, Primary Open-Angle Glaucoma, and Preperimetric Glaucoma and Healthy Controls. ( 30720005 )
2019
24
Rates of Ganglion Cell-Inner Plexiform Layer Thinning in Normal, Open-Angle Glaucoma and Pseudoexfoliation Glaucoma Eyes: A Trend-Based Analysis. ( 30721926 )
2019
25
Analysis of pattern electroretinogram signals of early primary open-angle glaucoma in discrete wavelet transform coefficients domain. ( 30725244 )
2019
26
Polymorphism rs7961953 in TMTC2 gene is not associated with primary open-angle glaucoma in a Saudi cohort. ( 30729851 )
2019
27
Increased prelaminar tissue thickness in patients with open-angle glaucoma and type 2 diabetes. ( 30730917 )
2019
28
Evaluation of Antiglaucomatous Drops on Conjunctival Thickness in Patients with Primary Open-Angle Glaucoma. ( 30758244 )
2019
29
Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. ( 30758653 )
2019
30
Migraine and increased risk of developing open angle glaucoma: a population-based cohort study. ( 30760249 )
2019
31
The Association of Oxidative Stress Status with Open-Angle Glaucoma and Exfoliation Glaucoma: A Systematic Review and Meta-Analysis. ( 30766729 )
2019
32
Effect of systemic antihypertensives on change in intraocular pressure after initiating topical prostaglandins for primary open-angle glaucoma. ( 30774300 )
2019
33
Comprehensive measurements of hydroxylinoleate and hydroxyarachidonate isomers in blood samples from primary open-angle glaucoma patients and controls. ( 30778084 )
2019
34
Measurement of Structural Parameters of the Lamina Cribrosa in Primary Open-Angle Glaucoma and Chronic Primary Angle-Closure Glaucoma by Optical Coherence Tomography and Its Correlations with Ocular Parameters. ( 30783031 )
2019
35
Ocular dialysis disequilibrium-Management of intraocular pressure during hemodialysis of open angle glaucoma: A case report and review of the literature. ( 30785657 )
2019
36
Effects of Trabeculectomy on Waveform Changes of Laser Speckle Flowgraphy in Open Angle Glaucoma. ( 30786279 )
2019
37
Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study. ( 30790180 )
2019
38
Transient ciliochoroidal detachment after 360-degree suture trabeculotomy ab interno for open-angle glaucoma: 12-month follow-up. ( 30792522 )
2019
39
Endoscopic cyclophotocoagulation (ECP) for open angle glaucoma and primary angle closure. ( 30801132 )
2019
40
Diagnostic power of laser speckle flowgraphy-measured optic disc microcirculation for open-angle glaucoma: analysis of 314 eyes. ( 30801940 )
2019
41
The Association Between the Transforming Growth Factor Beta-1 -509C>T Gene Polymorphism and Primary Open Angle Glaucoma in North Eastern Iran. ( 30805396 )
2019
42
Significant Association and Increased Risk of Primary Open Angle Glaucoma with TGFB2 Rs991967 Gene Polymorphism in North Eastern Iranian Patients. ( 30805402 )
2019
43
Effect of subconjunctival injection with conbercept as an adjuvant to filtration surgery for open angle glaucoma: a prospective randomized interventional 6-month follow-up study. ( 30809478 )
2019
44
Comprehensive sequencing of the myocilin gene in a selected cohort of severe primary open-angle glaucoma patients. ( 30816137 )
2019
45
Serum Bile Acids Level in Patients with Primary Open Angle Glaucoma. ( 30817500 )
2019
46
Border Tissue Morphology is Spatially Associated with Focal Lamina Cribrosa Defect and Deep-Layer Microvasculature Dropout in Open-Angle Glaucoma. ( 30825418 )
2019
47
Comparing the efficacy of trabeculectomy and diode laser cyclophotocoagulation in primary open-angle glaucoma. ( 30830546 )
2019
48
Greater Severity of Glaucomatous Damage in Eyes With Than Without Choroidal Microvasculature Dropout in Open-Angle Glaucoma. ( 30835291 )
2019
49
Differential Efficacy of Combined Phacoemulsification and Endocyclophotocoagulation in Open-angle Glaucoma versus Angle Closure Glaucoma. ( 30839415 )
2019
50
Association between rs4938723 polymorphism and the risk of primary open-angle glaucoma (POAG) in a Chinese population. ( 30861198 )
2019

Variations for Open-Angle Glaucoma

Expression for Open-Angle Glaucoma

Search GEO for disease gene expression data for Open-Angle Glaucoma.

Pathways for Open-Angle Glaucoma

Pathways related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 ELN LOXL1 LTBP2 MMP1 OPTC TGFB2
2
Show member pathways
10.79 ELN LOXL1 LTBP2 TGFB2

GO Terms for Open-Angle Glaucoma

Cellular components related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.26 ELN LOXL1 LTBP2 TGFB2
2 extracellular matrix GO:0031012 9.02 ELN LOXL1 LTBP2 MMP1 OPTC

Biological processes related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.02 CRYAA CYP1B1 OPA1 SIX6 WDR36
2 positive regulation of xenophagy GO:1904417 8.96 OPTN TBK1

Molecular functions related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 8.8 ELN LTBP2 OPTC

Sources for Open-Angle Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....